Keywords: Otsuka, EMEA, Abilify, Antidepresant, Schizophrenia

Otsuka withdraws EU its application for an extension of indication for Abilify

Article | 20 November 2009

Print This

The European Medicines Agency(EMEA) has been formally notified by Otsuka Pharmaceutical Europe, a unit of the Japanese drugmaker, of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in